Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.
Source: BioPharma Dive
You may also like
SMC recommends VEOZA for moderate to severe menopausal...
SMC backs Columvi combination for second-line lymphoma...
Bristol Myers Squibb’s New Drug Application for...
Exonate appoints Olav Hellebø as CEO
Immune Evasion Uncovered by Virome-Wide Ubiquitin...
Genetic Map Opens Door to Development of New Therapies...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.